TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06411925: A Multi-center, Randomized, Double-blinded, Active-controlled, Non-inferiority, Phase 4 Trial to Evaluate the Efficacy and Safety of Atock Dry Syrup Sama With Acute Bronchitis Patients

Sponsor: SamA Pharmaceutical Co., Ltd · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 296 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT06411925 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06411925 Rescue Dossier →